NASDAQ:ATEC - Alphatec Stock Price, News & Analysis

$5.88
+0.17 (+2.98 %)
(As of 09/19/2019 04:00 PM ET)
Today's Range
$5.71
Now: $5.88
$5.95
50-Day Range
$4.68
MA: $5.48
$6.20
52-Week Range
$1.18
Now: $5.88
$6.35
Volume439,565 shs
Average Volume439,626 shs
Market Capitalization$352.39 million
P/E RatioN/A
Dividend YieldN/A
Beta1.41
Alphatec Holdings, Inc, a medical technology company, focuses on the design, development, and promotion of products for the surgical treatment of spine disorders. Its product portfolio and pipeline address the cervical, thoracolumbar, and intervertebral regions of the spine; and cover various spinal disorders and surgical procedures. The company offers MIS products consisting of Battalion Lateral Spacer System and Squadron Lateral Retractor, Illico Minimally Invasive Surgery System, and BridgePoint Spinous Process Fixation System; and fixation products, such as Arsenal Screw System and Zodiac Spinal Fixation Systems. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:ATEC
CUSIP02081G10
Phone760-431-9286

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$91.69 million
Book Value$0.41 per share

Profitability

Net Income$-28,980,000.00

Miscellaneous

Employees195
Market Cap$352.39 million
Next Earnings Date11/14/2019 (Estimated)
OptionableNot Optionable

Receive ATEC News and Ratings via Email

Sign-up to receive the latest news and ratings for ATEC and its competitors with MarketBeat's FREE daily newsletter.


Alphatec (NASDAQ:ATEC) Frequently Asked Questions

What is Alphatec's stock symbol?

Alphatec trades on the NASDAQ under the ticker symbol "ATEC."

How were Alphatec's earnings last quarter?

Alphatec Holdings Inc (NASDAQ:ATEC) posted its quarterly earnings data on Wednesday, July, 24th. The medical technology company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by $0.05. The medical technology company earned $27.32 million during the quarter, compared to the consensus estimate of $25.37 million. Alphatec had a negative net margin of 45.29% and a negative return on equity of 211.15%. View Alphatec's Earnings History.

When is Alphatec's next earnings date?

Alphatec is scheduled to release their next quarterly earnings announcement on Thursday, November 14th 2019. View Earnings Estimates for Alphatec.

What guidance has Alphatec issued on next quarter's earnings?

Alphatec issued an update on its FY 2019 earnings guidance on Wednesday, July, 24th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $104-109 million, compared to the consensus revenue estimate of $100.86 million.

What price target have analysts set for ATEC?

3 analysts have issued twelve-month target prices for Alphatec's stock. Their predictions range from $6.00 to $7.00. On average, they anticipate Alphatec's stock price to reach $6.6667 in the next twelve months. This suggests a possible upside of 13.4% from the stock's current price. View Analyst Price Targets for Alphatec.

What is the consensus analysts' recommendation for Alphatec?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alphatec in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Alphatec.

What are Wall Street analysts saying about Alphatec stock?

Here are some recent quotes from research analysts about Alphatec stock:
  • 1. According to Zacks Investment Research, "Alphatec Holdings, Inc. is a medical technology company focused on the design, development, manufacturing and marketing of products for the surgical treatment of spine disorders. The Company's principal product offering includes a variety of spinal implant products and systems consisted of components, such as spine screws and rods, spinal spacers, plates, and various biologics offerings. Alphatec Holdings, Inc. is headquartered in Carlsbad, California. " (5/13/2019)
  • 2. HC Wainwright analysts commented, "We are maintaining our Buy rating of ATEC and our 12-month price target of $4.00 per diluted share. We derive our price target based on: 1) an EV-to-sales multiple analysis assuming 10% discount rate and using a 3.0x multiple on projected 2025 sales of $244M; and 2) a discounted cash flow analysis using the projected free cash flow to the firm through 2025 and assuming a 10% discount rate and 3% terminal growth rate. Using the average of the two methods, we arrive at a 12-month price target of $3.87 per share, which we round to $4.00." (1/14/2019)

Has Alphatec been receiving favorable news coverage?

Headlines about ATEC stock have been trending negative recently, InfoTrie reports. The research group identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Alphatec earned a coverage optimism score of -2.9 on InfoTrie's scale. They also assigned media stories about the medical technology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for Alphatec.

Who are some of Alphatec's key competitors?

What other stocks do shareholders of Alphatec own?

Who are Alphatec's key executives?

Alphatec's management team includes the folowing people:
  • Mr. Patrick S. Miles, Exec. Chairman & CEO (Age 53)
  • Mr. Craig E. Hunsaker, Exec. VP of People & Culture, Corp. Sec. and Gen. Counsel (Age 55)
  • Mr. Terry M. Rich, Consultant (Age 51)
  • Mr. Jeffrey P. Rydin, Director (Age 52)
  • Mr. Jeffrey G. Black, Exec. VP & CFO (Age 50)

Who are Alphatec's major shareholders?

Alphatec's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (2.61%), Vanguard Group Inc. (1.47%), Penn Capital Management Co. Inc. (0.78%), HighTower Advisors LLC (0.59%), Renaissance Technologies LLC (0.46%) and River & Mercantile Asset Management LLP (0.37%). Company insiders that own Alphatec stock include Craig E Hunsaker, Evan Bakst, Jeffrey G Black and Kelli Mari Howell. View Institutional Ownership Trends for Alphatec.

Which institutional investors are selling Alphatec stock?

ATEC stock was sold by a variety of institutional investors in the last quarter, including Penn Capital Management Co. Inc.. Company insiders that have sold Alphatec company stock in the last year include Craig E Hunsaker and Jeffrey G Black. View Insider Buying and Selling for Alphatec.

Which institutional investors are buying Alphatec stock?

ATEC stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., River & Mercantile Asset Management LLP, River & Mercantile Asset Management LLP, Vanguard Group Inc., Spears Abacus Advisors LLC, Jane Street Group LLC, Bank of New York Mellon Corp and HighTower Advisors LLC. Company insiders that have bought Alphatec stock in the last two years include Evan Bakst and Kelli Mari Howell. View Insider Buying and Selling for Alphatec.

How do I buy shares of Alphatec?

Shares of ATEC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Alphatec's stock price today?

One share of ATEC stock can currently be purchased for approximately $5.88.

How big of a company is Alphatec?

Alphatec has a market capitalization of $352.39 million and generates $91.69 million in revenue each year. The medical technology company earns $-28,980,000.00 in net income (profit) each year or ($0.58) on an earnings per share basis. Alphatec employs 195 workers across the globe.View Additional Information About Alphatec.

What is Alphatec's official website?

The official website for Alphatec is http://www.atecspine.com/.

How can I contact Alphatec?

Alphatec's mailing address is 5818 EL CAMINO REAL, CARLSBAD CA, 92008. The medical technology company can be reached via phone at 760-431-9286 or via email at [email protected]


MarketBeat Community Rating for Alphatec (NASDAQ ATEC)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  227 (Vote Outperform)
Underperform Votes:  279 (Vote Underperform)
Total Votes:  506
MarketBeat's community ratings are surveys of what our community members think about Alphatec and other stocks. Vote "Outperform" if you believe ATEC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATEC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/19/2019 by MarketBeat.com Staff

Featured Article: What is Cost of Debt?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel